Research programme: small molecule therapeutics - Odyssey Thera/Pfizer
Latest Information Update: 14 Oct 2009
At a glance
- Originator Odyssey Thera
- Developer Odyssey Thera; Pfizer
- Class Small molecules
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Oct 2009 Preclinical development is ongoing in the USA